APOE and neurodegenerative disease: Fifty-nine individuals were identified at maximum risk with levels of mercury above 10 μg/g and the presence of APOE4. This study also supports that ApoE4, in addition to a possible pharmacodynamic effect, may influence pharmacokinetically the mercury exposure causing a higher mercury bioaccumulation, which may lead to later neurodegenerative diseases with aging.